3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
37
Liver Neoplasms
18
Neoplasm Metastasis
17
Colorectal Neoplasms
13
Cholangiocarcinoma
11
Pancreatic Neoplasms
9
Lung Neoplasms
8
Colonic Neoplasms
8
Breast Neoplasms
8
Barrett Esophagus
7
Recurrence
6
Carcinoma, Renal Cell
6
Carcinoma, Non-Small-Cell Lung
6
Thyroid Neoplasms
5
Rectal Neoplasms
5
Thyroid Nodule
4
Pain
4
Neoplasms
4
Kidney Neoplasms
4
Esophageal Neoplasms
4
Thyroid Cancer, Papillary
3
Biliary Tract Neoplasms
3
Agnosia
3
Thyroid Diseases
2
Prostatic Neoplasms
2
Leiomyoma
2
Hyperaldosteronism
2
Cancer Pain
2
Bile Duct Neoplasms
2
Uterine Cervical Neoplasms
1
Interventions
Propranolol
3
Portasystemic Shunt, Transjugular Intrahepatic
2
Liver Transplantation
2
tremelimumab
1
durvalumab
1
Radiofrequency Ablation
1
Carvedilol
1
Bevacizumab
1
6-acetylaminocaproic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hypertension, Portal
×
Radiofrequency Ablation
×
Clear all
NCT02192671
2022-01-18
HR-HCC/PHT
Guangxi Medical University
Phase 3
Unknown
120 enrolled